KR100943747B1 - Composition for Prevention and Treatment of Diabetes Mellitus with Lactobacillus gasseri BNR17 - Google Patents

Abstract

The present invention relates to a composition for preventing or treating diabetes, and more particularly, to a composition for preventing or treating diabetes containing Lactobacillus gaseri BNR17 strain isolated from human breast milk as an active ingredient. The composition of the present invention not only improves the hypoglycemic effect, but also improves the symptoms of multiplying, multiplying, and polyuria, which are typical symptoms of diabetes mellitus, and is separated from breast milk, so it is excellent for human safety. It can be usefully used as a composition for the prevention or treatment of diabetes.

Lactobacillus gastritis, diabetes, hypoglycemic effect, weight loss inhibition, feeding amount, drinking water, feces

Description

Composition for prevention and treatment of Diabetes Mellitus with Lactobacillus gasseri BNR17}

1 is a comparison of the 16S rRNA sequences of Lactobacillus gazeri BNR17 lactobacillus and Lactobacillus gazeeri KC26 lactic acid bacteria (GENBANK Accession No .: AF243156).

Figure 2 is a graph comparing the weight gain of the control group and the group ingesting Lactobacillus gaseri BNR17.

◆; Control, ▲; Lactobacillus gasteria BNR17 administration group

Figure 3 is a graph comparing the daily feeding amount of the control group and the group ingesting Lactobacillus gaseri BNR17.

Blue bar; Control, yellow bars; Lactobacillus gasteria BNR17 administration group

Figure 4 is a graph comparing the daily drinking water of the control group and the group ingesting Lactobacillus gaseri BNR17.

Blue bar; Control, yellow bars; Lactobacillus gasteria BNR17 administration group

FIG. 5A is a graph showing urinary excretion and fecal variance for 3 days in the control group and the group ingesting Lactobacillus gasteria BNR17.

Blue bar; Control, yellow bars; Lactobacillus gasteria BNR17 administration group

FIG. 5B is a photograph showing urinary excretion and feces in the cage for 3 days of the control group and the group ingesting Lactobacillus gasteria BNR17.

Figure 6 is a graph showing the change in blood glucose levels after 16 hours fasting of the control group and the group ingested Lactobacillus gastri BNR17.

Blue bar; Control, yellow bars; Lactobacillus gasteria BNR17 administration group

7A and 7B are graphs showing the results of glucose tolerance test of the control group and the group ingesting the Lactobacillus gasery BNR17 on day 0 and day 35, respectively.

◆; Control, ▲; Lactobacillus gasteria BNR17 administration group

8A to 8E are graphs showing blood chemical analysis results of the control group and the group ingesting Lactobacillus gasi BNR17, and blood cholesterol, blood glucose, high density lipoprotein (HDL), and blood LDL (low) over time, respectively. density lipoprotein) and triglyceride (TG) in blood.

Blue bar; Control, yellow bars; Lactobacillus gasteria BNR17 administration group

9 is a graph showing the weight change of the group ingested the control group, Lactobacillus gaseri BNR17 and the like. The numbers in parentheses in BNR17 in the graph represent multipliers of 10 in CFU.

10 is a graph showing the change in the feed amount of the group ingesting the control group, Lactobacillus gaseri BNR17.

FIG. 11 is a graph showing the change in the average amount of negative drinking water during the 12 weeks of the control group, Lactobacillus gaseri BNR17, etc. group.

12 is a graph showing the change in the mean fecal variation during the 12 weeks of the group ingested the control group, Lactobacillus gaseri BNR17 and the like.

Figure 13 is a graph showing the fasting blood glucose change of the group ingested the control group, Lactobacillus gaseri BNR17.

14 is a graph showing the post-prandial blood sugar change of the groups ingested the control group, Lactobacillus gaseri BNR17, and the like.

15A to 15E are graphs showing sugar load test results after 0, 3, 6, 9 and 12 weeks after ingestion of the control group, Lactobacillus gaseri BNR17, and the like.

▲; Control group; Rosiglitazone, ◇; Acarbose, ●; BNR17 (7),

×; BNR17 (8), ○; BNR17 (9), -; BNR17 (10)

16 is a graph showing the results of histological analysis of the pancreas of the group ingested the control group, Lactobacillus gaseri BNR17.

(A) control, x 200

(B) Acarbose, x 200

(C) Acarbose, x 200

(D) BNR 17 (10), x 200

(E) BNR 17 (10), x 200

The present invention relates to the use of probiotic lactic acid bacteria, and more particularly, the novel lactic acid bacteria of the genus Lactobacillus having probiotic activity and hypoglycemic effect such as superior acid resistance, bile resistance and antimicrobial activity isolated from human breast milk. It is about one use.

Probiotics are living microorganisms that, when ingested in sufficient quantities, act as beneficial to the host, such as humans and animals. Lactobacillus has been with human history as the best known probiotics, and its usefulness is increasing day by day as a microorganism having a very beneficial effect on human health. In recent years, research on lactic acid bacteria has been actively conducted, as well as general foods, as well as being developed as a health food and medicine, the application range is getting wider. Microorganisms belonging to lactic acid bacteria include Streptococcus genus, Pediococcus genus, Leuconostoc genus, Lactobacillus genus, Sporolactobacillus genus, and Bifidobacterium spp . Bifidobacterium ) microorganisms.

These lactic acid bacteria play an important role in maintaining intestinal health by decomposing nutrients and fiber ingested by animals while using them as energy sources, producing lactic acid and antibiotics, and inhibiting the growth of harmful bacteria in the intestine. In addition, lactic acid bacteria have been used to promote animal growth and feed utilization, increase resistance to disease, inhibit the growth of harmful bacteria, reduce mortality, inhibit the production of decaying toxic substances and produce various vitamins. However, in order for the lactic acid bacteria to exert such efficacy, it must reach the intestine safely, attach to the intestinal mucosa, and display its function. To do this, it must be a strain that can be directly attached to the intestine, and should be able to meet the basic conditions such as less destruction by gastric acid during oral administration, strong resistance to bile acids, and strong antibacterial ability against pathogens. do.

In addition, lactic acid bacteria to be used in foods or pharmaceuticals for humans may be the best effect when the source is human, especially lactic acid bacteria isolated from women's breast milk has been evaluated as more effective and wider safety. . However, most of the human-derived lactic acid bacteria discovered so far are mainly isolated from feces of newborns or feces of mothers who feed on breast milk. Lactobacillus Lactobacillus is also isolated from breast milk. reuteri ) species, and lactic acid bacteria belonging to other species have been rarely reported.

Diabetes, on the other hand, is a condition in which many glucose is excreted in the urine, causing many complications such as cataracts, skin ulcers, multiple-prone purulents, neuralgia and renal failure, and affecting (or causing disability) fat metabolism. This can cause serious problems in the body, such as from ciosis and falling into diabetic coma. Diabetes is largely classified into two types: Insulin Dependent Diabetes Mellitus (IDDM) and Non-Insulin Dependent Diabetes Mellitus (NIDDM). It is known to account for more than% (Park Kyung-soo. J. Ginseng Res., 2003, 56-61). As a method for preventing and treating type 2 diabetes, 1) dietary control, 2) exercise therapy, 3) oral hypoglycemic agents, and 4) insulin preparations are used. Among them, insulin secretion is used as a representative drug of oral hypoglycemic agents. Sulfonin urea promoting agent, metformin improving insulin resistance, glycazone family, and alpha-glycosidase inhibitor inhibiting glucose absorption. However, these oral hypoglycemic agents are limited in use due to side effects such as liver toxicity, weight gain, hypoglycemia and the like.

On the other hand, it has been reported that the effect of lactic acid bacteria on diabetes, if oral administration of Lactobacillus casei ( Lactobacillus casei ) to the type 1 diabetes in mice with alloxan (alloxan) only lowers the incidence of diabetes Rather, blood glucose levels have been reported (Matsuzaki T et al., 1997. APMIS. 637-642). In addition, administration of Lactobacillus cassia to KK-A ^y mice, transgenic animals of type 2, resulted in hypoglycemic and weight gain inhibition, changes in cytokines such as IFN-γ and IL-2, and plasma insulin levels. Was found (Matsuzaki T et al., Endocrine J., 1997, 44, 357-365). Yadav et al. Also found that rats fed a high-calorie diet ingested dahi containing Lactobacillus ashophilus and Lactobacillus casei , and blood glucose, plasma insulin, glucose tolerance, triglycerides, LDL, and blood It has been reported that the level of free fatty acids can be greatly reduced to lower the incidence of diabetes (Yadav H et al., Nutrition, 2007, 23, 62-68).

It is an object of the present invention to provide a composition for the prevention or treatment of diabetes, which is isolated from human breast milk and has lactic acid bacteria resistant to acidic pH and bile acids and strong intestinal adhesion, and which contains lactic acid bacteria belonging to the Lactobacillus gaseri species.

The present invention provides a composition for preventing or treating diabetes, comprising Lactobacillus gazeeri BNR17, an lactic acid bacterium isolated from human breast milk, as an active ingredient. Preferably, the composition may be provided in the form of a food or pharmaceutical composition.

The inventors of the present invention deposited the Lactobacillus geriatric BNR17 strain isolated from breast milk at the Korea Biotechnology Research Institute Gene Bank on January 23, 2006 (Accession No .: KCTC 10902BP, Korean Patent Application No. 2007-7011080).

The Lactobacillus gaseri BNR17 lactic acid bacteria is excellent in acid resistance, bile resistance and antibacterial activity, can be used as a seed for producing a variety of lactic acid bacteria fermented milk and fermented products, wherein the fermented milk food, such as yogurt, calpis, cheese, butter For example, fermented products include tofu, soybean paste, cheonggukjang, jelly, kimchi, but are not necessarily limited thereto. The fermented milk and fermented product can be easily prepared by replacing only the strain with the lactic acid bacteria strain of the present invention in a conventional manufacturing method.

As described above, the composition of the present invention may be a food or an additive for food, and the food is preferably a fermented food. In addition, the composition of the present invention may be in powder or granule form, and the powder or granule form may be easily prepared by a conventional method in the art.

According to a preferred embodiment of the present invention, as a result of conducting experiments on diabetic animals, the LTOBACIUS GASERI BNR17-administered group has a 20% or higher blood sugar drop compared to the control group (see FIG. 6), and compared to the control group in the glucose tolerance test. It shows an excellent hypoglycemic effect at about 50% level (see FIG. 7). In addition, the daily feeding and negative amounts showed a reduction of 20% and 40% or more in the BNR17-administered group, respectively, compared to the control group (see FIGS. 3 and 4, respectively). 5).

According to another embodiment of the present invention, even in the case of experiments with the addition of various concentrations of the Lactobacillus gaseri BNR17 administration group, oral hypoglycemic administration group, the Lactobacillus gaseri BNR17 administration group is less weight loss as the dose is increased (Refer to FIG. 9) A phenomenon of decrease in feed amount, negative water amount and fecal amount was observed (see FIGS. 10, 11 and 12). In addition, the higher the BNR17 dose, the smaller the increase in blood glucose and the pre- and post-prandial blood sugar decreased by up to 30% compared to the control group (see FIGS. 13 and 14).

These results indicate that Lactobacillus gastri BNR17 lactobacillus improves the polymorphism, the following, and polyuria, which are the typical symptoms of diabetes, and that the ability to produce indigestible polysaccharides can be used for the prevention and treatment of diabetes.

In preparing the lactic acid bacteria food of the present invention, the Lactobacillus gaseri BNR17 may be used independently or together with other ingredients with an acceptable carrier, or may be used in the form of a composition suitable for human or animal ingestion. That is, the lactic acid bacteria of the present invention can be added to foods that do not contain other probiotic bacteria and foods that already contain some probiotic bacteria. For example, in the production of the lactic acid bacteria food of the present invention, other microorganisms that can be used with the Lactobacillus gaseri BNR17 lactic acid bacteria are suitable for ingestion by humans or animals, and when ingested, inhibit pathogenic harmful bacteria or in the mammalian intestine. Any probiotic activity capable of improving microbial balance can be used without limitation. An example of such a probiotic microorganism is Saccharomyces in MRS (Saccharomyces), Candida (Candida), blood teeth (Pichia) and sat rulrop cis yeast (yeast), Aspergillus (Aspergillus) containing (Torulopsis), Rhizopus Perth ( Rhizopus), myuko (Mucor), penicillin (Penicillium) fungi and Lactobacillus bacteria (Lactobacillus), Bifidobacterium (Bifidobacterium), current Kono Stock (Leuconostoc), Lactococcus (Lactococcus), Bacillus (Bacillus), such as, Streptococcus ( Streptococcus ), Gropionibacterium ( Propionibacterium ), Enterococcus , and bacteria belonging to the genus Pediococcus ( Pediococcus ). Specific examples of suitable probiotic micro-organisms are busy with the serenity Mrs. Saccharomyces (Saccharomyces cerevisiae), Bacillus core Tangerine Lance (Bacillus coagulans ), Bacillus licheniformis , Bacillus subtilis subtilis ), Bifidobacterium bifidum , Bifidobacterium infantis infantis ), Bifidobacterium longum ), Enterococcus faecium ), Enterococcus faecalis ), Lactobacillus acidophilus ), Lactobacillus alimentarius ), Lactobacillus casei ), Lactobacillus curvatus ), Lactobacillus delbruckii ), Lactobacillus johnsonii ), Lactobacillus farciminus ), Lactobacillus gasseri ), Lactobacillus helveticus ), Lactobacillus rhamnosus ), Lactobacillus reuteri ), Lactobacillus sakei ), Lactococcus lactis ), Pediococcus acidilactici ), and the like. Preferably, by further comprising a probiotic microbial mixed bacteria having excellent probiotic activity and excellent immune activity enhancement and anticancer activity in the lactic acid bacteria food for preventing or treating diabetes of the present invention can further enhance the effect. . Examples of carriers that may be included in the lactic acid bacteria food of the present invention include extenders, high fiber additives, encapsulating agents, lipids, and the like, examples of which are well known in the art. Lactobacillus gaseri BNR17, an active ingredient of the composition of the present invention, may be in lyophilized or encapsulated form, culture suspension, dry powder or granule form.

The present invention also provides a pharmaceutical composition for preventing or treating diabetes, comprising an effective amount of Lactobacillus gaseri BNR17 (Accession Number: KCTC 10902BP) and an acceptable carrier.

The Lactobacillus gaseri BNR17 lactic acid bacteria may be orally administered in the form of a unit such as a tablet or capsule obtained by mixing with a pharmaceutical carrier and excipient, or an auxiliary active ingredient, which are usually selected according to the route of administration.

Suitable carriers, excipients and diluents for the pharmaceutical compositions of the invention include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, tragacanth rubber, gelatin, calcium silicate, microcrystalline cellulose , Polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like. The microbial composition of the present invention may further comprise lubricants, wetting agents, emulsifiers and suspending agents, preservatives, sweeteners or flavoring agents. The pharmaceutical compositions of the present invention can be prepared into enteric coating formulations using methods known in the art to reach the small intestine after passing through the stomach and rapidly release the active ingredient microorganism into the intestine.

In addition, the pharmaceutical compositions of the present invention may be prepared in a capsule form using conventional encapsulation methods. For example, pellets containing the microorganisms of the present invention that have been lyophilized using a standard carrier may be prepared and then filled into hard gelatin capsules. Alternatively, the suspension or dispersion may be prepared using the microorganism of the invention and any suitable pharmaceutical carrier, such as aqueous gum, cellulose, silicate or oil, and then the dispersion or suspension may be filled into soft gelatin capsules. .

The pharmaceutical compositions of the present invention may in particular be provided as enteric coated enteric preparations as oral unit dosage forms. "Enteric coating" within this specification refers to all known types of pharmaceutically acceptable coatings that are not degraded by gastric acid so that the coating is maintained, but in the small intestine is sufficiently degraded to allow the active ingredient to be released into the small intestine. Include. The “enteric coating” is maintained for at least 2 hours when contacting artificial gastric juice, such as HCl solution at pH 1, at 36 ° C. to 38 ° C., preferably afterwards, at an artificial level such as KH ₂ PO ₄ buffer solution at pH 6.8. Refers to a coating that degrades within 30 minutes in enteric juice.

The enteric coating is preferably coated in one core in an amount of about 16 to 30, preferably 16 to 25 mg or less. The enteric coating shows satisfactory results as an enteric coating when the thickness is 5 to 100 m, preferably 20 to 80 m. The enteric coating material may be appropriately selected from known polymeric materials, and suitable polymeric materials are described in a number of known publications (L. Lachman et al., The Theory and Practice of Industrial Pharmacy, 3rd edition, 1986, pp. 365-373; H. Sucker et al., Pharmazeutische Technologie, Thieme, 1991, pp. 355-359; Hagers Handbuch der pharmazeutischen Praxis, 4th edition, Vol. 7, pp. 739-742, and 766-778, (Springer Verlag, 1971); and Remington's Pharmaceutical Sciences, 13th edition, pp. 1689-1691 (Mack Publ., Co., 1970)), which contains cellulose ester derivatives, cellulose ethers, methylacrylate copolymers of acrylic resins and aerials of maleic and phthalic acid derivatives. Coalescing may be included in these.

The enteric coating can be prepared using conventional enteric coating methods that spray an enteric coating solution onto the core. Suitable solvents used in the enteric coating process include alcohols such as ethanol, ketones such as acetone, halogenated hydrocarbon solvents such as CH ₂ Cl _2, and mixed solvents of these solvents may be used. Softeners such as di-n-butylphthalate or triacetin may be added to the coating solution, preferably with a coating material to softener added to the coating solution at a ratio of about 0.05 to about 0.3. It is appropriate to carry out the spraying process continuously, and it is possible to adjust the spraying amount in consideration of the coating conditions. Spray pressure can be varied and generally satisfactory results are obtained with spray pressures of about 1 to about 1.5 bar.

The "pharmaceutically effective amount" of the pharmaceutical composition means the minimum amount of microorganisms that can reduce the amount of low sugars absorbed into the body in the intestine of a mammal, and the amount of microorganisms administered into the body by the composition of the present invention is body weight. Depending on the age, sex, health condition, diet, time of administration, mode of administration, severity of the disease, and the microorganisms and auxiliary active ingredients used, they may be appropriately adjusted.

The composition of the present invention may be administered to the subject individual at least once daily. Unit dosage refers to units that are physically separated to be suitable for unit administration for human subjects and other mammals, each unit containing a predetermined amount of the Lactobacillus gasteria BNR17 lactic acid bacterium exhibiting an appropriate pharmaceutical carrier and therapeutic effect. do. It is preferable that the unit for oral administration of an adult patient contains 0.1 g or more of said lactic acid bacteria, and the oral dose of the composition of the present invention is 0.1 to 10 g, preferably 0.5 to 5 g at a time. The pharmaceutically effective amount of the microorganism is 0.1 to 10 g / day. In addition, the total daily dose may be divided into several times and administered continuously as needed. The dosage ranges therefore do not in any way limit the scope of the invention.

In the case of taking the composition of the present invention periodically, the microorganisms of the present invention in the intestine not only competitively prevent the human body from absorbing sugars, but also convert the carbohydrates in the form of polysaccharides into the form of polysaccharides, which are absorbed in the body. And the non-digestible dietary fiber produced by the microorganism improves the growth conditions of the intestinal useful bacteria and stimulates the intestinal motility so that the composition of the present invention functions as a preventive and therapeutic agent for diabetes.

On the other hand, in order to maximize the hypoglycemic effect or diabetes prevention and treatment of the pharmaceutical composition of the present invention, it can include any oral hypoglycemic agent known to those skilled in the art in an appropriate amount, wherein the content range of the additive is repeated It can be easily determined by those skilled in the art through experiments and the like. Preferred examples of ingredients useful as additives include conjugated linoleic acid, polydextrose, inulin, guar gum, arabic gum, L-carteine ), Grape seed extract, fructooligosaccharides, xylooligosaccharides, raffinose, gluconic acid, champignon, polyanthocyanidines, lactulose ( lactulose, lactitol, lactosucrose, lactosucrose, ganoderma lucidum extract, ginseng (red ginseng) extract, stone extract, kelp extract, mulberry leaf extract, jujube seed extract, coriander extract, cabbage bellflower extract, yam fraction, Silkworm powder and the like, but is not limited thereto.

In addition, the present invention comprises the steps of preparing Lactobacillus gasery BNR17 (Accession No .: KCTC 10902BP); And it provides a method for producing a food for preventing or treating diabetes comprising the step of adding Lactobacillus gaseri BNR17 to the food in an effective amount.

In addition, the present invention comprises the steps of preparing a Lactobacillus gaseri BNR17 (Accession Number: KCTC 10902BP); And it provides a method for producing a pharmaceutical composition for preventing or treating diabetes comprising mixing a carrier in an effective amount of Lactobacillus gaseri BNR17.

Hereinafter, the present invention will be described in detail by way of examples.

However, the following examples are only for illustrating the present invention, and the content of the present invention is not limited by the following examples.

Example  1. Isolation of Lactic Acid Bacteria from Breast Milk

Women's breast milk within 2 weeks of delivery was properly diluted with phosphate buffer solution, and the stock solution and dilutions were plated on Lactobacillus selective medium. Colonies that were incubated at 37 ° C. for 2 to 3 days were separated by pure form and color. Gram staining and microscopic observation were performed on the isolated colonies to select only gram-positive and rod-shaped colonies.They were cultured in MRS liquid medium at pH 6.8 for 24 hours at 37 ° C to reduce the pH of the culture to 4.5 or less. Colonies were reselected. After 2 hours of incubation in MRS medium at pH 2.0, acid-resistant and bile-resistant lactobacillus strains were viable when cultured for 9 hours in MRS medium containing 0.3% oxgall, followed by 16S rRNA sequencing. ) Was identified as a strain belonging to the Lactobacillus gagella species (SEQ ID NO: 1, see Figure 1). The present inventors named the strain "Lactobacillus gazeeri BNR17", and deposited it at the Korea Biotechnology Research Institute Gene Bank on January 23, 2006 (Accession No .: KCTC 10902BP).

Example  2. Animal Experiment Ⅰ Using Type 2 Diabetes Model

<2-1> Experimental group  And lactic acid bacteria administration method

C57BLKS / J-db / db mice (female, 9 weeks old), a type 2 diabetes model, were divided into two groups, one group (control), 0.2 ml of PBS (pH 7.4) solution, and the other group (experimental group) Lactobacillus. Kassel BNR17 was suspended in PBS solution so that the final bacterial count was 10 ⁹ CFU / 0.2ml, and orally administered twice daily (morning and afternoon) for 5 weeks. Breeding environment is temperature 21 ± 2 ℃, humidity 55 ± 5%, ventilation times 15 ~ 17 times / hour, illuminance 150 ~ 300 Lux, and lighting 12 hours contrast (lighting up: 06:00, lighting out: 18:00) It was adjusted and kept constant for the duration of the experiment. Solid feed (Central Experimental Animal, Korea) and water (Autoclaved water) were fed and fed freely and fasted for 16 hours before autopsy and sampling.

In this experiment, the statistically significant difference between the substance treatment group and the control group was tested by Student's t-test, and p <0.05 was determined as a significant difference between the experimental groups.

<2-2> Experimental method and result

<2-2-1> weight measurement

During the experiment, body weight was measured at a fixed time in a 16-hour fasting state.

As a result, the body weight was 42.45 ± 0.43g in the control group and 43.27 ± 2.45g in the Lactobacillus gasery BNR17 group before the start of the experiment, but from day 21, the body weight and food efficiency ratio (Food Efficiency Ratio, FER) began to increase slowly compared to the control group, and at the end of the experiment, the control group gained about 101.9% weight gain, but the experimental group administered BNR17 showed about 107.4% weight gain (FIG. 2 and Table 1). In addition, the dietary efficiency was significantly higher than the control group. From this result, it was confirmed that the lactic acid bacteria have an effect of improving the weight loss caused by hyperglycemia.

group Weight (g) Weight gain (g / day) Initial weight Final weight Control 42.447 ± 0.427 43.233 ± 3.206 0.02 ± 0.089 BNR17 43.267 ± 2.452 46.452 ± 0.739 ^* 0.09 ± 0.098

In the table, ^* P <0.05.

<2-2-2> Feed , Negative water , Urinary excretion  And Feces  Measure

During the experimental period, the feed amount was measured at regular intervals at 7 day intervals, and the feed amount was calculated on a daily basis. In addition, the amount of drinking water was measured at regular time intervals every three days, and the amount of drinking water was calculated on a daily basis. In addition, after replacing the new litter in each group, the urine and feces were collected every three days to collect and weigh.

As a result, in the case of feeding amount, the control group averaged 6.44 g / day, whereas the BNR17-administered group showed an average of 5.10 g / day, which was 20.8% lower than that of the control group (FIG. 3). In the mean value of the negative values, the control group was 18.46 ml / day and the BNR17-administered group was 9.86 ml / day, showing a 46.6% reduction compared to the control group (FIG. 4). Also, in the urine excretion and fecal volume, the control group was 129.76 g / 3 days, and the BNR17-administered group was 61.74 g / 3 days showed a 52.4% reduction compared to the control (Figs. 5a and 5b). From the above results, it was confirmed that Lactobacillus gaseri BNR17, a lactic acid bacterium isolated from breast milk, has an excellent effect of improving the polymorphism, the following, and polyuria, which are typical symptoms of diabetes.

<2-2-3> blood sugar measurement

Blood glucose measurement was performed every 7 days, including before the start of the experiment, and blood glucose was measured by a blood glucose meter (AGM-2100, Olmedikus, Korea) after 16 hours of fasting and blood collection from the tail vein.

As a result, as shown in Figure 6, the control group before the start of the experiment was 190.3 ± 53.7 mg / ㎗, BNR17 administration group was 186.7 ± 57.6 mg / ,, but in the lactobacillus administration group, blood glucose concentration began to decrease from the 7th day of administration The mean concentration up to the end date was 223.31 ± 50.13 mg / dL for the control group and 173.56 ± 30.77 mg / dL for the BNR17, which was 49.75 mg / dL (22.3%) compared to the control group. From the above results, it was confirmed that BNR17 lactic acid bacteria had an excellent hypoglycemic effect.

<2-2-4> Sugar load test glucose tolerance test )

For the glucose tolerance test, glucose was orally administered to C57BLKS / J-db / db mice fasted for 16 hours at a dose of 500 mg / kg BW, and Lactobacillus gaseous BNR17 was administered at a dose of 1 × 10 ⁹ cfu / 0.2 ml. Oral administration 30 minutes before glucose administration. Thereafter, blood was collected from the tail vein at intervals of 0, 30, 60, 90, 120, and 150 minutes to measure blood glucose through a blood glucose meter.

In the control group and the BNR17-administered group, the glucose load test was performed after 35 days. No glucose concentration change was observed until 30 minutes after the administration of glucose (500 mg / kg BW), but 60, 90, 120, and 150 minutes had passed after administration. When the lactic acid group administration group, the blood glucose reduction effect was remarkable, it was confirmed that there is an excellent hypoglycemic effect of about 53% compared to the control group at the end of the experiment (Figs. 7a and 7b). In contrast, no decrease in glucose concentration was observed in the control group over the entire time period. From the above results, it was confirmed again that Lactobacillus gaseri BNR17 lactic acid bacteria had an excellent hypoglycemic effect.

<2-2-5> Blood chemistry  analysis

The control group and the BNR17-administered group were administered once every 7 days for 12 weeks, and then 0.5 ml of blood was collected through the orbital vein. The refrigerator was centrifuged at 3,000 rpm using a centrifugal centrifuge (HA-1000-3, Hanil, Korea). Centrifuged for a minute. Plasma separated by the centrifugation was stored in a cryogenic freezer (-80 ℃), blood TC (total cholesterol), HDL, LDL, triglycerides, glucose concentration using a blood biochemical analyzer (7020, Hitachi, Japan) Were repeated twice each.

Frequent lipid metabolism abnormalities in diabetics include increased triglycerides and cholesterol in the blood and a decrease in HDL-cholesterol. As a result of this analysis, the serum triglyceride content was slightly lower in the BNR17-treated group than in the control group. The effect of reducing the blood glucose concentration was shown to be lower than the control group, but the blood cholesterol, LDL-cholesterol and HDL-cholesterol content was not observed in the BNR17 administration group compared to the control group (Figs. 8A to 8E). From the above results, it was shown that the lactic acid bacteria of the present invention had no effect of improving abnormalities of lipid metabolism.

Example  3. Animal Testing Using Type 2 Diabetes Model Ⅱ

In order to clarify the diabetic prevention and treatment effect of Lactobacillus gastri BNR17, the present inventors have various concentrations of BNR17 administration group and rosiglitazone (ROC) and acarbose (Acarbose, Bayer, Germany) administration group. The same experiment as in Example 2 was repeated by adding.

<3-1> Preparation of lactic acid bacteria powder

The strain used in the experiment was prepared through the following lyophilization process. Lactobacillus gastri BNR17, frozen and stored at -70 ° C, was thawed in a 37 ° C thermostat and then inoculated in 1 passage medium (Lactobacilli MRS broth, Difco, USA) and incubated for 24 hours at 5% CO ₂ , 37 ° C It was. The passage 1 culture was inoculated in passage 2 medium (LFC medium, Table 5) so that the final concentration of 4% was incubated for 24 hours at 150 rpm, 37 ℃ conditions. The culture solution was inoculated in three passages (LFC medium) to a final concentration of 8%, incubated at 200 rpm and 37 ° C. for 11 hours, and then inoculated in 600 L LFC medium and incubated at 60 rpm and 37 ° C. for 13 hours.

The culture solution was cooled to 25 ° C., and then filled with nitrogen through a sterile SUS tube, followed by automatic transfer by pressure difference with a centrifuge, thereby obtaining a lactic acid bacteria cake. This was washed once with 100 L of sterile phosphate buffer, and then centrifuged to obtain lactic acid bacteria having a stable pH. : 1) and the culture solution was mixed. At this time, the mixture of the freeze-dried protector 25 ml per 1L of the culture solution was evenly mixed and the concentration of the freeze-dried protector was adjusted by adding purified water.

The mixture was slowly frozen in a freeze dryer, and when it reached -35 ° C, the pressure was lowered to -70 cmHg or lower and lyophilized for 48 hours or longer to obtain a dry powder having a moisture content of less than 5%. It was ground to prepare a powder raw material of the desired particle size and stored in the dark at 4 ℃.

Table 2: Components of LFC Medium

Composition Content (w / v%) Composition Content (w / v%) Hydrolyzed Casein Protein 321 0.5 Sodium acetate 0.5 Yeast Extract-0202 2.0 Magnesium sulfate 0.01 Dextrose 2.0 Manganese sulfate 0.005 Polysorbate 80 (Tween 80) 0.1 Calcium carbonate 1.0 Dipotassium Phosphate 0.2

The LFC medium was adjusted to pH 7.0 using 50% (w / v) NaOH, and hydrolyzed casein protein 321 in the components of the medium was manufactured by Tatua (New Zealand) and yeast extract-0202 by Bio springer (France). Was used.

<3-2> Experimental group  And administration method

C57BLKS / J-db / db mice (male, 4-5 weeks old), type 2 diabetes mellitus, were divided into 7 groups of 10 rats, and 0.3 ml of PBS (pH 7.4) containing lyophilized protective agent was added to the control group (db-control). Oral administration was performed, and the experimental group (db-BNR17) was orally administered 0.3 ml of PBS suspended in Lactobacillus gasi BNR17 to the final 10 ⁷ , 10 ⁸ , 10 ⁹ and 10 ¹⁰ CFU (2 times a day for 12 weeks). ). The other two groups were administered oral hypoglycemic agents, rosiglitazone (db-logiglitazone) and acarbose (db-acarbose) at 8 mg / kg body weight / day and 40 mg / kg body weight / day, respectively, to compare the effects. It was.

In this experiment, the experimental animal breeding environment was the same as in Example <2-2>, and the experimental results were verified using the ANOVA statistical program of SPSS 11.0 version, and p <0.05 was significantly different between the experimental groups. Was determined.

<3-3> Experimental method and result

<3-3-1> body weight and Feed  Measure

Body weight was measured once every 7 days, feed amount was measured every 7 days to calculate the results on a daily basis. In the case of the feeding amount, it is difficult to measure at daily intervals, so it was measured once every 7 days and then divided by 7 and expressed as a daily value.

As a result, the control group showed a significant weight loss due to diabetes, but the body weight of the rosiglitazone-administered group increased (p <0.05). Although the LTOBASYL GASERI BNR17-administered group was not significantly different, the higher the BNR17 dose, the lower the weight loss was, and the effect was better than that of Acarbose (FIG. 9).

In addition, the feeding amount was smaller in all experimental groups than the control group, especially in the Lactobacillus gaseri BNR17 administration group, the feeding amount was also decreased in proportion to the BNR17 dose (p <0.05, FIG. 10).

The results indicate that Lactobacillus gasteria BNR17 is able to prevent polyps and weight loss, one of the main symptoms of diabetes.

<3-3-2> Negative water  And Feces  Measure

The amount of drinking water was measured every three days, and the results were calculated on a daily basis. The fecal amount was measured by collecting feces excreted every three days after replacing the new litter.

As a result, in all groups except the control group, the negative amount and fecal volume were significantly decreased than the control group, and especially in the Lactobacillus gasery BNR17-administered group, the negative amount and fecal volume were decreased as the BNR17 dose was increased (p <0.05, FIG. 11). And FIG. 12).

The results indicate that Lactobacillus gasteria BNR17 can improve the urinary tract, which is the main symptom of diabetes, and the following phenomenon.

<3-3-3> Blood glucose measurement

Blood glucose was measured once every 7 days, pre-prandial blood glucose was measured by blood collection from the tail vein after 16 hours fasting, and post-prandial blood glucose was measured after 2 hours after feeding.

As a result, the blood glucose of the control group increased continuously during the experimental period, and showed 357.7 ± 115.1 mg / dl at 12 weeks. The BNR17-administered Lactobacillus gasteria group showed less blood glucose increase as the BNR17 dose increased, and the increase was not greater than that of the control group. In particular, the blood glucose of the group receiving 10 ¹⁰ CFU was 207.9 ± 95.9 mg / dL at 12 weeks, about 30.3% lower than that of the control group. The rosiglitazone-administered group showed normal blood glucose levels of 95.0 ± 10.5 mg / dL, and the acarbose-administered group showed a significant decrease of 237.5 ± 125.4 mg / dL (FIG. 13).

Post-prandial blood glucose also increased in control group for 12 weeks, while blood sugar level was 576.0 ± 32.2 mg / dL at 12 weeks, whereas Lactobacillus gaseri BNR17-administered group decreased overall with increasing dose during the experimental period, confirming the effect of BNR17 by dose. Could. Meanwhile, the acarbose-administered group, which showed a significant decrease in pre-prandial blood sugar, did not show a significant decrease in post-prandial blood sugar (FIG. 14).

<3-3-4> Party load  exam

The glucose tolerance test was performed at three-week intervals. Specifically, 1 g / kg body weight after 30 minutes of oral administration of rosiglitazone, acarbose, or Lactobacillus gastery BNR17 to C57BLKS / J-db / db mice fasted for 16 hours. Glucose was measured by oral administration of glucose at doses and withdrawal from the tail vein at intervals of 0, 30, 60, 90, 120 and 150 minutes.

As a result, the rosiglitazone-administered group showed hypoglycemic symptoms, and the acarbose-administered group showed no significant difference from the control group. However, the lactobacillus gaseri BNR17-administered group significantly decreased the blood glucose concentration as the experimental period elapsed. In particular, the dose-dependent effect of BNR17 was clearly confirmed by increasing the difference in blood glucose concentration according to the dose (FIGS. 15A to 15E).

<3-3-5> Glycated hemoglobin ( HbA1c ) Measure

Glycosylated hemoglobin was measured for blood glycated hemoglobin (HbA1c), a glycemic index at 6 week intervals.

As a result, the control group had an initial concentration of HbA1c of 4.7 ± 0.5% but significantly increased to 8.7 ± 0.6 mg / dL at 12 weeks, and there was no change in the rosiglitazone-administered group. The Lactobacillus gaseri BNR17-administered group was ineffective until 10 ⁹ CFU, but a significant decrease of 1.26% was observed when 10 ¹⁰ CFU was administered (Table 3).

Table 3: HbA1c changes in db / db mouse groups fed different experimental diets

sample 0 weeks 6 Weeks 12 Weeks db-control 4.700 ± 0.515 7.860 ± 0.598 8.700 ± 0.606 db-logiglitazone 4.480 ± 0.476 4.180 ± 0.507 ^*** 4.060 ± 0.358 ^*** db-arkabos 4.120 ± 0.217 4.900 ± 1.005 ^*** 5.620 ± 1.521 ^** db-BNR17 (7) 4.520 ± 0.753 7.540 ± 0.472 8.220 ± 0.614 db-BNR17 (8) 4.600 ± 0.255 7.520 ± 0.716 8.940 ± 0.859 db-BNR17 (9) 4.460 ± 0.261 6.940 ± 0.733 8.380 ± 0.931 db-BNR17 (10) 4.340 ± 0.207 6.800 ± 0.515 ^* 7.440 ± 0.623 ^**

* P <0.05, ** P <0.01, *** P <0.001

<3-3-6> long-term weight

The organ weight was measured 12 weeks later by dissecting all experimental animals and removing liver, kidney, spleen and pancreas.

As a result, the logigitazone-administered group was greatly enlarged at the time of visual observation, and the weight was also larger than other experimental groups. Hepatic GOP and GPT levels were also significantly greater than in other experimental groups, indicating that rosiglitazone can cause side effects in the liver. On the other hand, the Lactobacillus gaseri BNR17-administered group did not show any significant changes in all organs and did not cause toxicity or side effects (Table 4 and Table 5).

Table 4: Changes in organ weight of db / db mouse groups fed different experimental diets

Table 5: Liver numbers in db / db mouse groups fed different experimental diets

sample liver Height ^{1 )} spleen interest Testicular adipose tissue db-control 3.050 ± 0.522 0.567 ± 0.064 0.104 ± 0.046 0.252 ± 0.075 2.382 ± 0.507 db-logiglitazone 4.578 ± 0.716 0.484 ± 0.047 0.089 ± 0.016 0.285 ± 0.184 2.545 ± 0.400 db-acabose 2.949 ± 0.355 0.520 ± 0.037 0.078 ± 0.038 0.252 ± 0.067 2.795 ± 0.125 db-BNR17 (7) 3.736 ± 0.777 0.610 ± 0.094 0.100 ± 0.090 0.260 ± 0.070 2.607 ± 0.166 db-BNR17 (8) 3.174 ± 0.540 0.569 ± 0.068 0.099 ± 0.039 0.261 ± 0.053 2.639 ± 0.519 db-BNR17 (9) 3.538 ± 0.748 0.616 ± 0.066 0.169 ± 0.107 0.261 ± 0.046 2.827 ± 0.335 db-BNR17 (10) 3.274 ± 0.639 0.520 ± 0.087 0.086 ± 0.043 0.274 ± 0.056 2.618 ± 0.174

¹⁾ The average of two kidney weights.

sample GOT (IU / l) GPT (IU / l) 0 weeks 12 Weeks 0 weeks 12 Weeks db-control 152.240 ± 60.998 215.160 ± 90.036 90.340 ± 58.990 188.120 ± 30.586 db-logiglitazone 168.240 ± 47.548 591.000 ± 209.451 ^** 92.080 ± 30.154 605.650 ± 213.399 ^** db-arkabos 157.060 ± 45.366 209.520 ± 65.026 78.400 ± 19.947 241.600 ± 44.697 db-BNR17 (8) 115.540 ± 27.380 212.440 ± 119.915 77.840 ± 22.270 196.920 ± 130.089 db-BNR17 (10) 143.020 ± 42.531 292.960 ± 60.911 81.140 ± 41.126 281.040 ± 107.395

** P <0.01

<3-3-7> Histological Analysis of the Pancreas

The pancreas was examined for the effects of Lactobacillus gasteria BNR17 and oral hypoglycemic agents on diabetic cells through histological analysis using H & E staining.

As a result, the proliferation of islet cells was observed in the acarbose and BNR17 10 ¹⁰ CFU-administered groups, while the morphological changes of interest were not observed in the control and other administration groups (FIG. 16).

Production Example  1. Preparation of Fermented Milk

Using skim milk powder, raw milk with the nonfat milk content adjusted to 8-20 wt% was sterilized at 72-75 ° C. for 15 seconds. After the sterilized crude oil was cooled to a certain temperature, the Lactobacillus gaseri BNR17 strain of the present invention was inoculated at a concentration of 10 ⁶ cfu / ml and cultured until pH 4-5. After completion of the culture, the culture was cooled. Meanwhile, the syrup is prepared by dissolving 0.1-50% by weight of juice concentrate, 0.1-20% by weight of dietary fiber, 0.5-30% by weight of glucose, 0.1-15% by weight of oligosaccharide, 0.001-10% by weight of calcium, and 0.0001-5% by weight of vitamin. It was. The syrup prepared in this way was sterilized, cooled, mixed and stirred at a predetermined ratio with the culture solution, homogenized, and then packaged in a container to prepare fermented milk. The fermented milk thus prepared showed good results in terms of flavor, physical properties and overall taste.

Production Example  2. Preparation of Lactic Acid Bacteria Powder

Lactobacillus gastri BNR17 of the present invention was inoculated in MRS liquid medium at a concentration of 10 ⁶ cfu / ml and pH-control fermentation (pH-control fermentation) was performed at 37 ° C for 18-24 hours. pH control was performed at pH 5.7 ± 0.2 with 30% by volume NaOH as neutralizing agent. After completion of the culture, the cells were recovered by centrifugation at 10,000 × g at 4 ° C. Prepare a protective agent containing 5% by weight skim milk, 2.5% by weight whey, 5% by weight sucrose with respect to the total composition, and mixed the recovered cells in the same amount with the protective agent through a lyophilizer Powdered. The dry powder of the Lactobacillus gastri BNR17 thus prepared showed a viable cell count of 1 × 10 ¹¹ cfu / g or more. The protective agent may further contain 10 wt% trehalose, 10 wt% maltodextrine, and 7.5 wt% lactose.

Production Example  3. Preparation of lactic acid bacteria preparation

Using lactic acid bacteria powder prepared in Preparation Example 2, lactic acid bacteria preparations such as lactic acid bacteria foods and formal preparations were prepared. To this end, 10 wt% of oligosaccharides, 20 wt% anhydrous glucose, 5 wt% of fructose, 2 wt% of vitamin C, 5 wt% of fruit powder, 5 wt% of aloe, 15% by weight of dietary fiber and 18% by weight of chaff were mixed and packaged by dispensing a predetermined amount in a stick or bottle. The lactic acid bacterium preparation thus prepared maintained a viable cell number of 5 × 10 ⁸ cfu / g or more.

As described above, the composition for preventing or treating diabetes of the present invention containing the Lactobacillus gaseri BNR17 strain has an excellent effect of improving not only an excellent hypoglycemic effect, but also a phenomenon of polymorphism, next and polyuria, which are typical symptoms of diabetes. By having it, it can be usefully used for the purpose of preventing or treating diabetes.

<110> Bioneer Corporation <120> Composition for Prevention and Treatment of Diabetes Mellitus          with Lactobacillus gasseri BNR17 <130> 2007-DPA-152 <160> 2 <170> KopatentIn 1.71 <210> 1 <211> 840 <212> DNA <213> Lactobacillus gasseri BNR17 <400> 1 gctgactcct ataaaggtta tcccaccggc tttgggtgtt acagactctc atggtgtgac 60 gggcggtgtg tacaaggccc gggaacgtat tcaccgcggc gtgctgatcc gcgattacta 120 gcgattccag cttcgtgtag gcgagttgca gcctacagtc cgaactgaga acggctttca 180 nagatccgct tgccttcgca ggttcgcttc tcgttgtacc gtccattgta gcacgtgtgt 240 agcccaggtc ataaggggca tgatgacttg acgtcatccc caccttcctc cggtttgtca 300 ccggcagtct cattagagtg cccaacttaa tgatggcaac taatgacaag ggttgcgctc 360 gttgcgggac ttaacccaac atctcacgac acgagctgac gacagccatg caccacctgt 420 ctcagcgtcc ccgaagggaa ctcctaatct cttaggtttg cactggatgt caagacctgg 480 taaggttctt cgcgttgctt cgaattaaac cacatgctcc accgcttgtg cgggcccccg 540 tcaattcctt tgagtttcaa ccttgcggtc gtactcccca ggcggagtgc ttaatgcgtt 600 agctgcagca ctgagaggcg gaaacctccc aacacttagc actcatcgtt tacggcatgg 660 actaccaggg tatctaatcc tgttcgctac ccatgctttc gagcctcagc gtcagttgca 720 gaccagagag ccgccttcgc cactggtgtt cttccatata tctacgcatt ccaccgctac 780 acatggagtt ccactctcct cttctgcact caagttcaac agtttctgat gcaattctcc 840                                                                          840 <210> 2 <211> 840 <212> DNA <213> Lactobacillus gasseri KC26 <400> 2 gctgactcct ataaaggtta tcccaccggc tttgggtgtt acagactctc atggtgtgac 60 gggcggtgtg tacaaggccc gggaacgtat tcaccgcggc gtgctgatcc gcgattacta 120 gcgattccag cttcgtgtag gcgagttgca gcctacagtc cgaactgaga acggctttca 180 gagatccgct tgccttcgca ggttcgcttc tcgttgtacc gtccattgta gcacgtgtgt 240 agcccaggtc ataaggggca tgatgacttg acgtcatccc caccttcctc cggtttgtca 300 ccggcagtct cattagagtg cccaacttaa tgatggcaac taatgacaag ggttgcgctc 360 gttgcgggac ttaacccaac atctcacgac acgagctgac gacagccatg caccacctgt 420 ctcagcgtcc ccgaagggaa ctcctaatct cttaggtttg cactggatgt caagacctgg 480 taaggttctt cgcgttgctt cgaattaaac cacatgctcc accgcttgtg cgggcccccg 540 tcaattcctt tgagtttcaa ccttgcggtc gtactcccca ggcggagtgc ttaatgcgtt 600 agctgcagca ctgagaggcg gaaacctccc aacacttagc actcatcgtt tacggcatgg 660 actaccaggg tatctaatcc tgttcgctac ccatgctttc gagcctcagc gtcagttgca 720 gaccagagag ccgccttcgc cactggtgtt cttccatata tctacgcatt ccaccgctac 780 acatggagtt ccactctcct cttctgcact caagttcaac agtttctgat gcaattctcc 840                                                                          840  

Claims (9)

A composition for preventing or treating diabetes comprising Lactobacillus gaseri BNR17 (Accession No .: KCTC 10902BP) as an active ingredient. The method of claim 1, The composition is a composition, characterized in that the food or food additives. The method of claim 2, The food is a composition, characterized in that the fermented food. The method of claim 3, The fermented food is a composition, characterized in that selected from the group consisting of yogurt, calpis, cheese, butter, tofu, miso, Cheonggukjang, jelly and kimchi. The method of claim 1, The composition is characterized in that the powder or granule form. A pharmaceutical composition for preventing or treating diabetes comprising an effective amount of Lactobacillus gaseri BNR17 (Accession No .: KCTC 10902BP) and an acceptable carrier. The method of claim 6, The pharmaceutical composition is a composition, characterized in that it has a formulation selected from the group consisting of tablets, capsules and enteric preparations. Preparing Lactobacillus gastri BNR17 (Accession No .: KCTC 10902BP); And Method of producing a food for preventing or treating diabetes comprising the step of adding Lactobacillus gaseri BNR17 to the food in an effective amount. Preparing Lactobacillus gastri BNR17 (Accession No .: KCTC 10902BP); And A method of making a pharmaceutical composition for preventing or treating diabetes, comprising mixing an effective amount of an acceptable carrier with an effective amount of Lactobacillus fern BNR17.

Images